Edwards Lifesciences Corporation

EW Healthcare Medical Devices

Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS fell 26.3%, free cash flow grew 142.8% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.

86.60 1.50 −1.70%
Market cap
$50.8B
P/E
49.8×
Fwd P/E
30.7×
Dividend yield
—
F-score
5/9
Altman Z
11.54
Beneish M
−2.48
Dividend safety
n/a

Edwards Lifesciences Corporation (EW) Operating cash flow

Alert me on Operating cash flow

Edwards Lifesciences Corporation's operating cash flow for fiscal 2025 was $1.6B, up 194.2% from $542.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.7B. Over the past ten years it has ranged from $542.3M (fiscal 2024) to $1.7B (fiscal 2021); the current reading is higher than 91% of that period. Edwards Lifesciences Corporation ranks 10th of 149 Medical Devices companies by operating cash flow.

Operating cash flow, annual

Embed this chart

Annual newest first

Period Operating cash flow Change
FY2025 $1.6B 194.15%
FY2024 $542.3M (39.46%)
FY2023 $895.8M (26.47%)
FY2022 $1.2B (29.67%)
FY2021 $1.7B 64.29%
FY2020 $1.1B (10.87%)
FY2019 $1.2B 27.65%
FY2018 $926.7M (7.39%)
FY2017 $1.0B 42.06%
FY2016 $704.4M 28.14%

Quarterly newest first

Period Operating cash flow Change
Jun 2026 $651.9M 1,388.36%
Mar 2026 $43.8M (90.29%)
Dec 2025 $450.9M (21.40%)
Sep 2025 $573.7M 97.69%
42 more quarters

Against its own ten years

Low $542.3M High $1.7B
Ten-year median $1.0B
Current reading's percentile 91

Operating cash flow against peers

What Operating cash flow is

Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.

Reported line item

The full definition of Operating cash flow →

More on EW